Citigroup Comments on Potential Pfizer - AstraZeneca Acquisition

Earlier today Citi analysts noted that AstraZeneca

is still the most attractive acquisition target for Pfizer

. However, the analysts believe there is only a 25 percent chance that Pfizer will return to the table after August 26 and instead see December as the more likely approach. The team noted an offer would need to be over $60 for Pfzer to secure the deal. Looking at AstraZeneca, the Citi analysts say the company may potentially seek a near-term acquisition of Actelion to help boost its EPS.